Nasdaq gnlx.

Dec 1, 2023 · A high-level overview of Genelux Corporation (GNLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily ...WESTLAKE VILLAGE, Calif. - Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000 Index and small-cap Russell 2000 at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.Jul 6, 2023 · The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023.

View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news. Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...Genelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the …

WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Web

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...Fintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ...WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...

Shares of Genelux ( GNLX -7.61%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ...

Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million ...

Find the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Genelux Corporation ( NASDAQ: GNLX) has filed to raise $30 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing ...WebNasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...WebWESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...

Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of November 1 ...About. Genelux Corporation, a Delaware · Highlight. A company researching a leading · Exchange. NASDAQ. Listing Date · NASDAQ. Listing Date. 01/26/2023.20. 11. 2023 ...What happenedShares of Genelux Corporation (NASDAQ: GNLX) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company ...Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...

GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...

After-Hours Trades ... Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...WebGenelux (NASDAQ:GNLX – Get Free Report) had its price target reduced by equities researchers at Benchmark from $38.00 to $30.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “speculative buy” rating on the stock. Benchmark’s price target points to a potential upside of 170.27% from the company’s …WebNasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). An ...Genelux Corporation (NASDAQ:GNLX) declined 11.7% to $14.95. NatWest Group plc (NYSE:NWG) shares fell 11.5% to $4.49 after the company reported third-quarter earnings and lowered its full-year net ...WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...

In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.

Genelux Corporation Common Stock (GNLX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...10% least volatile stocks in US Market. 2.9%. Stable Share Price: GNLX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week. Volatility Over Time: GNLX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.So far, 2023 has been a great year for Genelux Corporation (NASDAQ:GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily ...Genelux Co. (NASDAQ:GNLX – Free Report) – Equities researchers at HC Wainwright issued their FY2023 EPS estimates for Genelux in a research report issued on Monday, November 27th.HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.17) per share for the year. HC Wainwright currently has a “Buy” …WebNov 23, 2023 · Nelly Dodson. November 23, 2023. Business. Genelux Corp (NASDAQ:GNLX)’s traded shares stood at 76372.0 during the last session. At the close of trading, the stock’s price was $11.19, to imply an increase of 7.80% or $0.81 in intraday trading. The GNLX share’s 52-week high remains $40.98, putting it -266.22% down since that peak but still ... Jun 29, 2023 · WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebGenelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX... What happenedShares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech ...On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts.A high-level overview of Genelux Corporation (GNLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...Nov 30, 2023 · Genelux Corp (NASDAQ: GNLX) has experienced a rise in its stock price by 11.85 compared to its previous closing price of 10.46. However, the company has seen a gain of 12.72% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) — Genelux […] IPO preview: IPOs that could start trading next week include biopharma Genelux Corporation (NASDAQ:GNLX) and tech firm Beamr Imaging Ltd . The quiet periods on Corebridge Financial ...Instagram:https://instagram. catch up 401kdividend vanguardgrenadiers suvwsj customer service 0. Barclays PLC, a global financial services firm, recently acquired a new stake in Genelux Co. (NASDAQ:GNLX) during the first quarter of this year. According to its latest filing with the Securities and Exchange Commission (SEC), Barclays purchased 33,178 shares of Genelux’s stock, valued at approximately $920,000.Genelux Stock Price, News & Analysis (NASDAQ:GNLX) $11.90 +0.20 (+1.71%) (As of 11/30/2023 ET) Compare Today's Range $11.46 $12.00 50-Day Range … best small boat insuranceinvested in apple Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. iso20022 crypto list Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX... Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE.Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.